BDX — Becton Dickinson (Stock)

Price: $215.71 · 1 day: +0.55% · 5 days: +1.01% · 1 month: +15.13% · YTD: +41.38%
As of 2026-11-12 21:00 UTC.

52-week range: $140.11 – $216.85 (currently at 99% of the range).

The brief

BDX is in an uptrend, momentum firm. $225 is the level overhead; $200 the first support below.

6 of 6 technical checks lean bullish.

TrendUptrend · above 50-day & 200-day
MomentumRSI 73.8 · overbought · MACD bullish
Trend strengthADX 48.6 · strong trend
Location+13.3% vs 50-day MA
52-week range+0% from high · +53% from low
VolatilityATR 4.76 · ~2.2%/day

Key levels

LevelTypeDistance
$225.0 (resistance)round4.31%
$250.0 (resistance)round15.9%
$200.0 (support)round-7.28%
$192.42 (support)swing zone-10.8%
$190.32 (support)sma 50-11.77%

Indicators

RSI (14)73.82MACD7.3465
ADX (14)48.6ATR (14)4.76
50-day average$190.32200-day average$168.19

Next earnings: 2026-11-05. BDX earnings date, time and past reactions.

Becton Dickinson (BDX) stock analysis, November 3, 2026: Uptrend intact below $200 resistance, earnings two days away

Report of 2026-11-03, updated 2026-11-09.

Update, November 9, 2026

Since the November 3 report, Becton Dickinson (BDX) has rallied to $216.38, up 2.12% on the day and 8.95% over the past five days, while the S&P 500 slipped 0.03% and the healthcare sector XLV rose 2.11%.

The picture holds – the stock remains above the 200 round support and the 188.75 sma_50, still below the breakout trigger of a daily close above 225 round on volume above its 20‑day average. The stop at 198.82 (based on 200 minus a quarter of the 4.73 ATR) and the target of 250 round remain unchanged.

BDX’s earnings release on SEC EDGAR confirmed a strong quarter, with revenue up 5.6% and adjusted EPS of $4.15, supporting the bullish momentum. The stock’s 5‑day outperformance of +8.95% versus the market and sector underscores the continued strength of the uptrend.

Update, November 4, 2026

BDX jumped 5.7% on November 4, closing at a new 52-week high of $209.50, as the stock extended its 5-day gain to 7.3% versus a 5.7% rise in XLV and a 0.5% decline in SPY. The move came ahead of tomorrow's earnings, with the healthcare sector broadly stronger (+3.1% on the day).

The picture holds. The stock remains above its 40-week average and the daily trend is aligned with the weekly uptrend. The previous invalidation level of $186.99 (swing zone) has been replaced by a higher trigger: a weekly close below $187.27 (50-day SMA) would change the picture. Support now sits at $200.00 (round), then $192.42 (swing zone) and $187.27. Resistance is at $225.00 (round) and $250.00 (round).

Momentum is stretched — RSI is at 72.9, and volume is 105% of the 20-day average. Historically, new 52-week highs have led to higher prices a month later 63.1% of the time (median +1.36%), while RSI above 70 has been followed by gains 58.7% of the time (median +0.92%). The mean analyst target of $195.57 sits 7.1% below the current price, but the high target is $225.00. Earnings are due November 5.

Becton, Dickinson and Company (BDX) trades at $197.68 on November 3, 2026, 1.4% below its October 22 peak of $200.42 and two days before earnings. The balance of evidence for the next 2–6 weeks leans positive, with medium conviction. The daily and weekly trends agree and the stock leads the S&P 500, but it trails its own sector, and the breakout math stops just short of 3 to 1.

Why it matters

No company-specific news item explains the current move. The news feed for BDX is empty, so the price action has to speak for itself. The stock has gained 11.8% in a month, 32.4% in six months and 29.6% so far this year, which puts it well ahead of the S&P 500's 10.5% year-to-date gain. A rally of that size has been built over months, not on one headline.

The last five days show how that strength is divided. The S&P 500 (SPY) fell 2.1%, so the broad market was a headwind. The healthcare sector fund XLV rose 2.8%, so the sector was a tailwind. BDX rose 1.4%, which is 1.5 points less than the sector. The stock held up against a falling market but did not keep pace with its peers. Today it slipped 0.5% while the market gained 0.2%, and the pullback came on volume about 36% below the 20-day average. Light-volume dips of that kind usually reflect a lack of sellers rather than a rush of them, though they also show buyers are not pressing the stock toward $200.

There is no published debate to cite, so the argument comes from the numbers. The bull case is that BDX is a leader: it beats the S&P 500 by 7.6 points over 50 days and 14.9 points over 200 days, and it sits above both its 50-day average ($186.87) and its 200-day average ($166.33). The counter-case is that the stock has not led its own sector, trailing XLV by 0.9 points over 50 days. The sector is doing much of the lifting, and a stock that only matches a hot sector has less in reserve if the sector cools.

Valuation adds a caution. Fourteen analysts rate the stock a buy, but the mean price target of $195.57 sits slightly below the current price, which is 1.1% above it. The targets range from $165 to $225. The consensus is positive on the company yet does not assign the shares more upside from here. The high target of $225 is the only one that implies a clear move higher, and it matches the upper resistance level on the chart.

What the evidence says

On the long term, the thesis is intact. Price is above its 40-week average and its 10-week average. The 52-week range runs from $138.67 to $200.42, and the stock is 42.6% above the low and within 1.4% of the high. That is a mature uptrend near its highs, not a recovery or a base. The 200-day average is $166.33, well below the price, which shows how far the stock has run from its long-term baseline.

For the next 2–6 weeks, the balance of evidence leans positive, with medium conviction: two of four points are in place. The daily trend runs with the weekly uptrend, and the stock leads the S&P 500 over 50 days. The 14-day RSI is 65.5, which is strong but not stretched. The point that is missing is relative strength against the sector, where BDX lags XLV and is therefore going against the trend of its group.

The strongest case against this reading is that the move may be running out of room. Volume is 35.8% below its 20-day average, which means the approach to $200 has little participation. The stock lags its sector over both five days and 50 days, and it trades above the mean analyst target. If earnings disappoint, the sector tailwind that has helped BDX in recent weeks would not protect it. These points are why conviction is medium and not higher. They do not tip the balance because the price structure is still intact: the dip from the peak is small, and the stock is well above its supports.

Levels that matter

The structure holds above $192.42, a swing zone from earlier trading, and the first sign of damage would be a break below it. The trend ends below $186.99, another swing zone that sits just above the 50-day average at $186.87. Below that, the next supports are $175.46, the 200-day average at $166.33 and $163.83. The closer levels matter most: $192.42 is about $5 under the current price, while $186.99 is roughly one and a half average daily ranges further down, with the 14-day ATR at $3.70.

The breakout level is a daily close above $200 on volume above its 20-day average. That is a round number and also the level just under the October 22 peak. From $200, the next target is $225, a round number that also matches the highest analyst target. Against a stop at $191.49, which is the $192.42 swing zone minus a quarter of ATR, the math gives 2.9 to 1. That does not reach the 3 to 1 that makes a breakout worth the risk. A higher target or a stop closer to $200 would be needed to get there, and neither is on the chart today.

What would change the picture

The rule is a weekly close below $186.99. That would break the swing zone that anchors the weekly trend and put price under the 50-day average, ending the pattern of higher lows that supports the positive reading. The non-price fact that could do it is a cut to the company's full-year outlook at earnings on November 5, 2026. A weaker forecast would challenge the idea that BDX deserves to trade near its highs when the consensus target is already below the price.

What to watch

Latest BDX news

Explore more

Interactive BDX chart and analyst chat · Market terminal — movers, signals and news · Use MarketCrew inside Claude · Use MarketCrew inside ChatGPT · Top gainers today · 52-week highs